Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor
Ali, Eslam M.H and Abdel-Maksoud, Mohammed S. and Hassan, Rasha Mohamed and Mersal, Karim I. and Ammar, Usama M. and Se-In, Choi and He-Soo, Han and Kim, Hee-Kwon and Lee, Anna and Lee, Kyung-Tae and Oh, Chang-Hyun (2021) Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor. Bioorganic and Medicinal Chemistry, 31. 115969. ISSN 0968-0896 (https://doi.org/10.1016/j.bmc.2020.115969)
Preview |
Text.
Filename: Ali_etal_BMC_2020_Design_synthesis_and_anti_inflammatory_activity_of_imidazol_5_yl_pyridine.pdf
Accepted Author Manuscript License: Download (2MB)| Preview |
Abstract
P38α/MAPK14 is intracellular signalling regulator involved in biosynthesis of inflammatory mediator cytokines (TNF-α, IL-1, IL-6, and IL-1b), which induce the production of inflammatory proteins (iNOS, NF-kB, and COX-2). In this study, drug repurposing strategies were followed to repositioning of a series of B-RAF V600E imidazol-5-yl pyridine inhibitors to inhibit P38α kinase. A group 25 reported P38α kinase inhibitors were used to build a pharmacophore model for mapping the target compounds and proving their affinity for binding in P38α active site. Target compounds were evaluated for their potency against P38α kinase, compounds 11a and 11d were the most potent inhibitors (IC50 = 47 nM and 45 nM, respectively). In addition, compound 11d effectively inhibited the production of proinflammatory cytokines TNF-α, 1L-6, and 1L-1β in LPS-induced RAW 264.7 macrophages with IC50 values of 78.03 nM, 17.6 µM and 82.15 nM, respectively. The target compounds were tested for their anti-inflammatory activity by detecting the reduction of Nitric oxide (NO) and prostaglandin (PGE2) production in LPS-stimulated RAW 264.7 macrophages. Compound 11d exhibited satisfied inhibitory activity of the production of PGE2 and NO with IC50 values of 0.29 µM and 0.61 µM, respectively. Molecular dynamics simulations of the most potent inhibitor 11d were carried out to illustrate its conformational stability in the binding site of P38α kinase.
ORCID iDs
Ali, Eslam M.H, Abdel-Maksoud, Mohammed S., Hassan, Rasha Mohamed, Mersal, Karim I., Ammar, Usama M. ORCID: https://orcid.org/0000-0002-7218-641X, Se-In, Choi, He-Soo, Han, Kim, Hee-Kwon, Lee, Anna, Lee, Kyung-Tae and Oh, Chang-Hyun;-
-
Item type: Article ID code: 76324 Dates: DateEvent1 February 2021Published28 December 2020Published Online21 December 2020Accepted25 October 2020SubmittedSubjects: Medicine > Therapeutics. Pharmacology Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 05 May 2021 10:14 Last modified: 13 Dec 2024 11:53 URI: https://strathprints.strath.ac.uk/id/eprint/76324